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Recurrence patterns after 
maximal surgical resection and 
postoperative radiotherapy in 
anaplastic gliomas according to the 
new 2016 WHO classification
Jung Ho Im1, Je Beom Hong2, Se Hoon Kim  3, Junjeong Choi4, Jong Hee Chang  5, Jaeho Cho  1 
& Chang-Ok Suh1
We assessed the appropriateness of current radiotherapy volume for WHO grade III gliomas. The records 
of 73 patients with WHO grade III gliomas who received postoperative radiotherapy between 2001 and 
2013 were retrospectively reviewed. Based on the 2016 WHO classification, 25/73 (34.2%) patients had 
anaplastic oligodendroglioma (AO), IDH-mutant and 1p/19q-codeleted; 11/73 (15.1%) patients had 
anaplastic astrocytoma, IDH-mutant; and 37/73 (50.7%) patients had anaplastic astrocytoma, IDH-
wildtype. The extent of resection (EOR) was total in 43 patients (58.9%). The median follow-up time 
was 84 months. The 5-year overall survival was 65.4%. Of 31 patients with documented recurrences, 
20 (64.5%) had infield gross tumor volume (GTV) failure, six (19.4%) had clinical target volume (CTV)/
marginal failure, and five (16.1%) had outfield failure/seeding. In 13 recurrences among 43 patients who 
underwent gross total resection (GTR), six (46.2%) had infield CTV/marginal failure. However, among 
30 patients for whom GTR was not conducted, infield GTV failure was dominant (77.8%). Seventeen 
patients with AO, IDH-mutant and 1p/19q-codeleted who underwent GTR experienced no recurrence. 
In conclusion, maximal surgical resection and postoperative radiotherapy resulted in a favorable 
prognosis, especially in patients with GTR, IDH mutation, and 1p/19q codeletion. Patterns of failure 
differed by EOR.
The current recommendation for the World Health Organization (WHO) grade III glioma treatment is maximal 
safe resection followed by radiotherapy (RT). Additional chemotherapy (CTx) with procarbazine, lomustine, and 
vincristine (PCV) has been proven to effectively prolong the survival of patients with anaplastic oligodendro-
glial tumors in the EORTC Brain Tumor Group Study 26951 and RTOG 9402 trials1,2. In both trials, initial RT 
volume included T2-weighted abnormality plus a 2–2.5-cm margin (45–50.4 Gy in 25–28 fractions), and boost 
field was T1 abnormality (enhanced lesion and/or non-enhanced mass) plus a 1–1.5-cm margin (9–14.4 Gy in 
5–8 fractions; total radiation dose was 59.4 Gy in 33 fractions). At our institution, physicians perform irradiation 
according to the same policy. The survival outcome of grade III gliomas differs according to the histological 
subtypes, anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), and anaplastic oligodendroglioma 
(AOA). However, recurrence patterns according to the histological subtypes have not been well studied. Most 
studies on recurrence patterns were mainly conducted before 19953–7, and most included high-grade gliomas 
together with WHO grade III and IV gliomas, with a strong majority of the patients with glioblastoma. Trials for 
grade III tumors alone are rare, and no study has reported recurrence patterns according to histological subtypes. 
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Although the extent of surgical resection is a strong prognostic factor8–11 and may affect the recurrence pattern, 
recurrence patterns according to surgical extent have not yet been well defined.
Recently, molecular profiling, including 1p/19q codeletion, isocitrate dehydrogenase gene (IDH) mutations, 
and O6-methylguanine-DNA-methyltransferase gene (MGMT) promoter methylation, were shown to be more 
useful in identifying the prognostic subgroups of WHO grade III gliomas12–16. The International Society of 
Neuropathology-Haarlem guidelines propose that diagnoses of central nervous system tumors should be “lay-
ered” with histological classification, WHO grade, and molecular information in the form of an integrated diag-
nosis to better define the disease17. The revised WHO Classification of Tumors of the Central Nervous System 
2016 has considered these developments and released a new diagnostic concept that combines histological and 
molecular parameters18.
We hypothesized that recurrence patterns differ by extent of resection (EOR) and histological subtypes, as well 
as molecular subtypes. Therefore, we analyzed recurrence patterns with respect to RT target volume and com-
pared the differences between patient characteristics, such as EOR, and the 2016 WHO classifications.
Methods and Materials
Study design and patient characteristics. Seventy-three patients with WHO grade III gliomas who 
underwent surgical resection and postoperative RT between 2001 and 2013 and were followed-up for >6 months 
Characteristic (n = 73) No. of patients (%)
Age (years)
 ≤50 55 (75.3)
 >50 18 (24.7)
Sex
 Male 39 (53.4)
 Female 34 (46.6)
Preoperative KPS
 90–100 21 (28.8)
 70–80 52 (71.2)
Main presenting symptom
 Seizure 25 (34.2)
 Headache 21 (28.8)
 Other 27 (37.0)
Pathological diagnosis according to the 2007 WHO classification
 AA 24 (32.9)
 AO 25 (34.2)
 AOA 24 (32.9)
1p/19q status
 Codeletion present 32 (43.8)
 Codeletion absent 41 (56.2)
IDH1 status
 Mutated 36 (49.3)
 Wild type 37 (50.7)
2016 WHO classification
 AO, IDH-mutant and 1p/19q-codeleted 25 (34.2)
 AA, IDH-mutant 11 (15.1)
 AA, IDH-wildtype 37 (50.7)
MGMT promoter status
 Methylated 49 (67.1)
 Unmethylated 24 (32.9)
Extent of resection
 Gross total resection 43 (58.9)
 Subtotal resection 18 (24.7)
 Partial resection 8 (11.0)
 Biopsy 4 (5.5)
Chemotherapy
 Yes 45 (61.6)
 No 28 (38.4)
Table 1. Baseline characteristics of all patients. KPS, Karnofsky Performance Status; WHO, World 
Health Organization; AA, Anaplastic Astrocytoma; AO, Anaplastic Oligodendroglioma; AOA, Anaplastic 
Oligoastrocytoma; IDH, isocitrate dehydrogenase gene; MGMT, O6-methylguanine-DNA-methyltransferase gene.
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with magnetic resonance imaging (MRI) were retrospectively analyzed. Patients who received whole-brain RT 
were not included in the study. None of the patients in this study had low-grade gliomas before being diagnosed 
with WHO grade III gliomas. The study protocol conformed to the ethical guidelines of the 1975 Declaration 
of Helsinki, as revised in 1983, and was approved by the institutional review board of Severance Hospital. The 
patient records/information were anonymized and de-identified prior to analysis; informed consent was not 
obtained from each participant.
The characteristics of all 73 patients are listed in Table 1. The median age was 38 years (range, 18–67 years), 
and 55 patients (75.3%) were <50 years old. All patients had a Karnofsky performance status of ≥70. Pathological 
diagnosis was made based on the 2007 WHO classification at initial diagnosis. Twenty-four patients (32.9%) had 
AA, 25 (34.2%) had AO, and 24 (32.9%) had AOA.
Surgery. All patients underwent preoperative MRI with gadolinium enhancement. Histological diagnosis 
and maximal safe tumor removal was performed by specialized neuro-oncological surgeons. Postoperative MRI 
Figure 1. Schematic examples with the definitions of RT target volumes and patterns of recurrences. “infield 
GTV failure”: tumor recurrence or disease progression entirely within GTV; “infield CTV failure”: tumor 
recurrence within CTV; “marginal failure”: consisting of recurrent tumor crossing CTV; and “outfield failure”: 
in all other cases, referring to recurrences outside the RT field.
Figure 2. Progression-free survival and overall survival rates for all 73 patients.
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was performed within 48 hours after surgery. EOR was determined on the basis of the operative findings and 
postoperative MRI, including postcontrast T1 and T2 fluid-attenuated inversion recovery (FLAIR) images. Gross 
total resection (GTR) was defined as complete resection of the enhanced and unenhanced masses and no obvious 
residual tumor. Subtotal resection (STR) was defined as resection of a gross tumor by ≥90%. Partial resection 
(PR) was defined as resection of a gross tumor by >50%. GTR was achieved in 43 patients (58.9%). STR or PR 
was performed in 18 (24.7%) and 8 (11.0%) patients, respectively. In four patients (5.5%), only biopsy (Bx) was 
performed.
Postoperative RT and CTx. RT was started 12–53 (median 22) days after surgery. Three-dimensional con-
formal RT was used to treat 63 patients (86.3%), and 10 patients (13.7%) were treated with intensity-modulated 
RT using tomotherapy. The computed tomography scan obtained at simulation and after reconstructed with a 
3-mm-slice thicknesses was fused to pre- and postoperative MRI data, including postcontrast T1 images and 
T2 or FLAIR images. Gross tumor volume (GTV) included the resection cavity and any gross residual tumor 
observed on postoperative MRI plus a 0.5–1-cm margin to compensate for the irregularity and uncertainty of 
the margin. The clinical target volume (CTV) was defined by GTV and hyperintense area on T2 FLAIR MRI 
plus a 1.5–2-cm margin accounting for potential microscopic extension. The planning target volume (PTV1) was 
CTV plus a 3-mm margin in all directions to account for daily setup uncertainty. A subsequent boost was given 
to PTV2, which was defined as GTV plus a 0.3-cm margin. The median total dose of PTV1 was 46 Gy (range, 
36–51) with 1.8–2 Gy per fraction. The median total dose of PTV2 was 60 Gy (range, 50–70). Three patients 
(4.1%) received <59 Gy.
Adjuvant CTx was administered according to the physician’s preference. Forty-five patients (61.6%) received 
adjuvant CTx. Twenty-two patients received RT plus concomitant TMZ followed by adjuvant TMZ, while 13 
patients received RT followed by TMZ. A median of six cycles of adjuvant TMZ was administered. Eight patients 
received PCV CTx after completion of RT.
Prognostic factor No. of patients
Progression free survival Overall survival
Median (m) 5/10-year (%) p-value Median (m) 5/10-year (%) p-value
Age (y) 0.112 0.299
 ≤50 55 143 64.7/59.7 158 69.9/58.9
 >50 18 50 45.8/45.8 50 49.7/49.7
Sex 0.245 0.416
 Male 39 143 51.9/51.9 158 61.4/52.9
 Female 34 130 69.9/62.1 NR 69.4/60.3
Preoperative KPS 0.617 0.951
 90–100 21 NR 64.3/64.3 NR 64.3/64.3
 70–80 52 130 58.7/53.6 158 65.9/55.3
1p/19q status <0.001 <0.001
 Codeletion present 32 NR 87.5/87.5 NR 90.0/90.0
 Codeletion absent 41 42 40.8/35.4 55 47.7/35.1
IDH1 status <0.001 0.001
 Mutated 36 NR 79.4/74.5 NR 83.9/74.6
 Wild type 37 40 42.1/38.8 50 47.5/40.4
2016 WHO classification 0.001 0.001
AO, IDH-mutant and 
1p/19q-codeleted 25 NR 88.0/88.0 NR 91.2/91.2
 AA, IDH-mutant 11 NR 63.6/53.0 NR 71.6/51.1
 AA, IDH-wildtype 37 40 42.1/38.8 50 47.5/40.4
MGMT promoter status 0.002 <0.001
 Methylated 49 NR 71.0/71.0 NR 73.9/73.9
 Unmethylated 24 45 38.3/27.3 50 48.1/26.7
Extent of resection <0.001 0.007
 Gross total resection 43 143 76.5/69.2 158 78.2/69.8
 Subtotal resection 18 NR 55.0/55.0 NR 60.2/52.7
 Partial resection-biopsy 12 28 16.7/16.7 49 41.7/20.8
Chemotherapy 0.970 0.701
 Yes 45 143 58.6/55.7 158 65.3/56.3
 No 28 130 63.0/56.0 NR 65.1/54.3
Table 2. Univariate analysis of prognostic factors regarding progression-free and overall survival. 
KPS, Karnofsky Performance Status; Dx, diagnosis; WHO, World Health Organization; IDH, isocitrate 
dehydrogenase gene; AO, Anaplastic Oligodendroglioma; AA, Anaplastic Astrocytoma; MGMT, O6-
methylguanine-DNA-methyltransferase gene; NR, not reached.
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Molecular biomarkers assessment. We retrospectively examined IDH1 mutation using a Ventana Bench 
Mark XT autostainer (Ventana Medical System, Inc., Tucson, AZ, USA) according to the protocol. The antibody 
used was anti-human IDH1 R132H mouse monoclonal antibody (Clone H09L, 1:80 dilution; Dianova, Hamburg, 
Germany). When the cytoplasmic expression of IDH1 R132H was identified in glioma cells, we considered the 
case as “mutant”/“positive.”
FISH analysis of 1p/19q status was performed using the LSI 1p36/1q25 and 19q13/19p13 Dual-Color Probe 
Kit (Abbott Molecular Inc., Abbott Park, IL, USA). Acquired images were interpreted by two neuropathologists 
as the basis for EURO-CNS protocols19. If the numbers of “deleted” nuclei exceed 50%, the tumor was consid-
ered to show a “deletion” for the targeted chromosome. MGMT gene promoter methylation was assessed by 
methylation-specific polymerase chain reaction as previously described20,21.
Thirty-two patients (43.8%) had 1p/19q codeletion, an IDH1 mutation was detected in 36 patients (49.3%), 
and an MGMT promoter was methylated in 49 patients (67.1%) (Table 1). Two pathologists independently 
re-reviewed the pathology and molecular biomarkers and confirmed the pathological diagnosis according to 
the 2007 WHO classification and 2016 WHO classification. We reclassified our 73 cases according to the 2016 
WHO classification: 25 patients (34.2%) with AO, IDH-mutant and 1p/19q-codeleted, 11 patients (15.1%) with 
AA, IDH-mutant, and 37 patients (50.7%) with AA, IDH-wildtype18. MGMT promoter status was significantly 
Figure 3. (A) Overall survival rate according to the 2016 WHO classification (AO, anaplastic oligodendroglioma; 
AA, anaplastic astrocytoma; IDH, isocitrate dehydrogenase gene). (B) Overall survival rate by extent of resection 
(GTR, gross total resection; STR, subtotal resection; PR, partial resection; Bx, biopsy).
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correlated with IDH mutation, 1p/19q codeletion, and the 2016 WHO classification (p < 0.05). More than 90% of 
patients with the IDH mutation or 1p/19q codeletion exhibited a methylated MGMT promoter status.
Patient follow-up and evaluations. Patients were followed up with MRI 1 month after RT, every 3 
months during the first 2 years, and every 6–12 months or when disease progression was suspected thereafter. 
Disease progression was defined as clinical progression based on an oncologist’s interpretation of imaging and 
clinical status, usually resulting in the change of treatment22. Pseudoprogression or radiation necrosis was differ-
entiated with true progression by subsequent MRI, which showed resolution of contrast-enhanced lesions with 
edema without any change in therapy23.
Serial MRI images were reviewed to determine first failures. All recurrence patterns were analyzed by a 
neuro-oncology team consisting of radiation oncologists, neurosurgeons, and neuroradiologists. Recurrences 
were defined as follows: “infield GTV failure” tumor recurrence or disease progression entirely within GTV; 
“infield CTV failure” tumor recurrence within CTV; “marginal failure” consisting of recurrent tumor crossing 
CTV; and “outfield failure” in all other cases referring to recurrences outside the RT field. The cerebrospinal fluid 
(CSF) seeding was defined as three or more non-contiguous lesions in addition to disease (stable or progression) 
at the primary site or leptomeningeal enhancement. Figure 1 illustrates schematic examples with the definitions 
of RT target volumes and patterns of recurrences.
Variable
PFS OS
HR (95% CI) p-value HR (95% CI) p-value
2016 WHO classification
AO, IDH-mutant and 
1p/19q-codeleted Reference Reference
AA, IDH-mutant 2.674 (0.618–11.580) 0.188 4.290 (0.816–22.558) 0.085
AA, IDH-wildtype 5.725 (1.688–19.412) 0.005 8.252 (1.919–35.484) 0.005
Extent of resection
GTR-STR Reference Reference
PR-Bx 3.017 (1.411–6.452) 0.004 2.405 (1.079–5.363) 0.032
Table 3. Multivariate analysis of prognostic factors for progression-free and overall survival. WHO, World 
Health Organization; AO, Anaplastic Oligodendroglioma; IDH, isocitrate dehydrogenase gene; AA, Anaplastic 
Astrocytoma; GTR, Gross Total Resection; STR, Subtotal Resection; PR, Partial Resection; Bx, Biopsy; PFS, 
Progression Free Survival; OS, Overall Survival; HR, Hazard Ratio; CI, Confidence Interval.
Recurrence
Type of recurrence
Infield GTV
Infield CTV/
marginal
Outfield/CSF 
seeding
All 31 20 6 5
2016 WHO classification
AO, IDH-mutant and 1p/19q-codeleted (n = 25) 3 (12.0%) 2 0 1
GTR (n = 17) 0 (0.0%) 0 0 0
STR (n = 7) 2 (28.6%) 1 0 1
PR-Bx (n = 1) 1 (100.0%) 1 0 0
AA, IDH-mutant (n = 11) 5 (45.5%) 4 1 0
GTR (n = 6) 1 (16.7%) 0 1 0
STR (n = 2) 2 (100%) 2 0 0
PR-Bx (n = 3) 2 (66.7%) 2 0 0
AA, IDH-wildtype (n = 37) 23 (62.2%) 14 5 4
GTR (n = 20) 12 (60.0%) 6 5 1
STR (n = 9) 4 (44.4%) 4 0 0
PR-Bx (n = 8) 7 (87.5%) 4 0 3
Extent of resection
GTR (n = 43) 13 (30.2%) 6 6 1
STR (n = 18) 8 (44.4%) 7 0 1
PR-Bx (n = 12) 10 (83.3%) 7 0 3
Table 4. Patterns of first recurrence according to the 2016 WHO classification and extent of resection. The 
numbers represent the number of patients with recurrences. Column 2 represents the number of patients in 
each subgroup with recurrence and their percentages are indicated in parentheses. GTV, Gross Tumor Volume; 
CTV, Clinical Target Volume; CSF, Cerebrospinal Fluid; WHO, World Health Organization; AO, Anaplastic 
Oligodendroglioma; IDH, isocitrate dehydrogenase gene; GTR, Gross Total Resection; STR, Subtotal Resection; 
PR, Partial Resection; Bx, Biopsy; AA, Anaplastic Astrocytoma.
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Statistical analysis. Progression-free survival (PFS) was calculated as the time from the date of operation 
to the first reported disease progression or death. Overall survival (OS) was calculated as the time from the date 
of operation to the date of death or last follow-up visit. Categorical variables were compared using the Chi-square 
test or Fisher’s exact test, as appropriate. Survival rates were calculated using Kaplan–Meier methods and com-
pared using the log-rank test. Multivariate analysis was performed using the Cox proportional hazards model and 
hazard ratio with a 95% confidence interval to identify prognostic factors. Criteria for the inclusion of variables 
in a multivariate analysis included statistical significance on univariate analysis and clinical relevance. P values of 
<0.05 indicated statistical significance.
Results
Survival outcome and toxicity. The median follow-up period was 55 months (range, 8–180 months) for 
all patients and 84 months (range, 30–180 months) for the surviving patients. The median follow-up period of 
the surviving patients with AO, IDH-mutant and 1p/19q-codeleted; patients with AA, IDH-mutant; and patients 
with AA, IDH-wildtype was 63 months, 78 months, and 98 months, respectively. At the time of analysis, 29 
patients (39.7%) had died 8–158 months after diagnosis (median, 32 months). The median PFS and OS were 
130 (range, 56–204 months) and 158 months, respectively. The 5- and 10-year PFS rates were 60.4% and 56.3%, 
respectively, and 5- and 10-year OS rates were 65.4% and 56.6%, respectively (Fig. 2). MRI imaging abnormalities 
suggestive of pseudoprogression or radiation necrosis were observed in 20 patients (27.4%). No patients were 
diagnosed with radiation necrosis on biopsy or surgical resection. No patients died from radiation necrosis.
Prognostic factors. The results of the univariate analysis of PFS and OS are summarized in Table 2. The 
univariate analysis showed that 1p/19q status, IDH1 status, pathological diagnosis according to the 2016 WHO 
classification, MGMT promoter status, and EOR were prognostic factors for PFS and OS (p < 0.05). The 5-year 
OS of patients with AO, IDH-mutant and 1p/19q-codeleted; patients with AA, IDH-mutant; and patients with 
AA, IDH-wildtype was 91.2%, 71.6%, and 47.5%, respectively (AO, IDH-mutant and 1p/19q-codeleted vs. 
AA, IDH-mutant, p = 0.041; AO, IDH-mutant and 1p/19q-codeleted vs. AA, IDH-wildtype, p < 0.001; AA, 
IDH-mutant vs. AA, IDH-wildtype, p = 0.257) (Fig. 3A). Patients with GTR had significantly better OS compared 
to patients with PR or Bx (p = 0.002) (Fig. 3B).
On multivariate analysis, GTR-STR had a significantly positive impact on PFS and OS (p < 0.05). Compared 
to patients with AA, IDH-wildtype, those with AO, IDH-mutant and 1p/19q-codeleted had significantly better 
PFS and OS (p < 0.05) (Table 3).
Recurrence rate and patterns of recurrence. Disease progression or recurrence was noted in 31 patients 
(42.4%) 3–143 months after diagnosis (median, 19 months). Twenty-seven of 31 failures (87.1%) occurred within 
60 months after the operation. Recurrence rates and patterns of recurrences were analyzed according to the 
2016 WHO classifications, as well as EOR (Table 4). Infield GTV failure was the dominant type of failure (20/31, 
64.5%). Outfield failure was observed in one patient, and CSF seeding occurred in four patients.
In patients with AO, IDH-mutant and 1p/19q-codeleted, recurrences were less commonly noted (3/25, 12%) 
than in those with AA, IDH-mutant (5/11, 45.5%) and AA, IDH-wildtype (23/37, 62.2%). In addition, 17 patients 
with AO, IDH-mutant and 1p/19q-codeleted who received GTR showed no recurrence. In the 12 recurrences 
among 20 patients with AA, IDH-wildtype who underwent GTR, five (41.7%) had infield CTV/marginal failure.
Recurrence rate was lower in patients with GTR/STR (21/61, 34.4%) than in those with PR-Bx (10/12, 83.3%). 
Recurrence patterns differed by EOR. A significant difference between the extent of resection and patterns of 
recurrence was noted in Fisher’s exact test (p < 0.05). In the STR and PR-Bx groups, most recurrences were infield 
GTV failures (14/18, 77.8%) without infield CTV/marginal failures. In contrast, six (46.2%) of the recurrences 
were CTV/marginal failures in the GTR group.
Discussion
Survival outcome according to the 2016 WHO classification was not previously reported because IDH analysis 
was not routinely performed until recently. By retrospectively examining IDH mutation, we confirmed that the 
prognosis of WHO grade III gliomas is largely dependent on the 2016 WHO classification. Since we administered 
a consistent RT volume during the study period, we could evaluate the effects of the 2016 WHO classifications 
as well as EOR on recurrence patterns. Although infield GTV failure was the most common pattern of failure 
overall, patterns of failure differed by EOR.
Recurrence rates varied according to the 2016 WHO classification. The recurrence rate was very low in 
patients with AO, IDH-mutant and 1p/19q-codeleted, and there were no cases of recurrence in patients with 
AO, IDH-mutant and 1p/19q-codeleted who underwent GTR. On the other hand, 23 of 37 patients with AA, 
IDH-wildtype developed recurrence, even after GTR (12/20, 60%), and the most common type of recurrence 
was infield GTV. These findings suggest that RT is less effective for AA, IDH-wildtype. Several studies showed 
that IDH mutation represents radiosensitive tumors and good prognosis24,25. The correlation between IDH and 
MGMT promoter methylation was suggested in several studies1,26, as observed in this study. Almost all AO 
patients with the IDH mutation demonstrated MGMT promoter methylation and had better prognosis. These 
findings may reflect the improved outcome of gliomas with IDH mutation.
Recurrence rates after GTR or STR were similar but much lower than those after PR-Bx. In patients with 
GTR, most recurrences (12/13) occurred in the patients with AA, IDH-wildtype, and approximately half of the 
recurrences was infield GTV failure and the other half was infield CTV/marginal failures (Table 4). We prescribed 
46–50 Gy to CTV. Therefore, a higher radiation dose to CTV can be considered for AA, IDH-wildtype. On the 
contrary, only one recurrence was noted in 23 GTR patients with AO, IDH-mutant and 1p/19q-codeleted or 
www.nature.com/scientificreports/
8SCIeNtIfIC RepoRtS |  (2018) 8:777  | DOI:10.1038/s41598-017-19014-1
AA, IDH-mutant. Therefore, we suggest that the current RT volume and dose prescription is appropriate for 
these patient groups. All patients treated with STR or PR-Bx showed progression with infield GTV or outfield/
CSF seeding 3–130 months (median, 14 months) after surgery. To overcome early infield GTV recurrences, dose 
escalation >60 Gy to the residual tumor or a combination of radiosensitizing drugs can be considered. There 
is insufficient evidence to prove that hypofractionated, hyperfractionated, and accelerated RT improved local 
control and OS in high-grade glioma patients27. Dose escalation is an important scheme in radiotherapeutic 
strategies. However, dose-escalation would be limited due to the risk of late toxicities. The role of TMZ has been 
assessed in a large international trial, CATNON. Interim analysis showed that adjuvant TMZ CTx was associated 
with significant survival benefits in patients with newly diagnosed 1p/19q non-co-deleted anaplastic glioma28.
Before arguing the appropriate RT volume, the tumor should be more accurately defined on imaging. MRI 
T2 FLAIR hyperintensity has traditionally been accepted as the target delineation of glioma. Contrast-enhanced 
lesions on T1-weighted images are regarded as more malignant tumors than non-enhanced lesions, and high radi-
ation doses are usually prescribed. Compared with glioblastomas, where GTV is defined as contrast-enhanced 
lesions, grade III gliomas often show mixed patterns of enhancing and non-enhancing tumor masses. Therefore, 
accurate delineation of tumor extent and identification of the most malignant parts are crucial for RT plan-
ning as well as surgery. Perfusion-weighted imaging is helpful to detect higher vascular tumors, which should 
be included in GTV29. Recently, amino acid PET imaging has been investigated for tumor extent and biopsy 
guidance; this showed that amino acid PET was superior to the standard MRI30. Currently, our institution uses 
amino acid PET for guiding tumor resection and RT planning. Metabolic imaging with MR spectroscopy to 
image the 2-hydroxyglutarate signal in the brain to detect oncogenic IDH1 mutations has been recently devel-
oped. It showed that the 2-hydroxyglutarate volume was larger than the FLAIR volume in approximately half of 
the IDH-mutant glioma patients31. These improved techniques may have implications for better RT planning and 
treatment outcomes.
The current study has important limitations that should be considered when interpreting our results. When a 
case was negative for IDH1 immunostaining results, we did not perform IDH1 and IDH2 sequencing as recom-
mended by Louis et al.18. Although the incidence of IDH1 mutation, except R132H and IDH2, is very rare32, it 
may be an important limitation. Although we performed surgery and postoperative RT using consistent methods, 
CTx was not controlled, which may be a confounding factor. The small number of patients is another critical 
limitation of our study. We observed different failure rates and different recurrence patterns for the histologi-
cal subtypes according to the 2016 WHO classification; however, the differences were not statistically signifi-
cant, probably due to the small number of patients. Despite these limitations, compared to previous institutional 
studies, this is the largest single-institutional cohort study that analyzed the failure patterns of grade III glioma 
patients. In addition, to the best of our knowledge, this is the first study that analyzed the treatment outcomes 
using the new 2016 WHO classification.
In conclusion, maximal surgical resection and postoperative RT, including peritumoral edema, resulted in a 
favorable prognosis, especially in patients with GTR, IDH mutation, and 1p/19q codeletion. We observed that 
patterns of failure differed according to EOR. Infield GTV failures and infield CTV/marginal failures were not 
uncommon in patients with AA, IDH-wildtype even after GTR. Further studies investigating the optimal RT 
volume and dose for AA, IDH-wildtype are needed.
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